Philly’s Biomeme has growth in its DNA

Growth appears to be in the DNA of Biomeme, a Philadelphia startup. In only a year, the company has raised significant funding, tripled its staff and is moving to larger offices. 

Biomeme “enables anyone to do mobile real-time DNA analysis on a smartphone,” explains co-founder Max Perelman. The company makes kits, hardware and software allowing users to easily isolate DNA from a variety of sample types (including blood, water and urine) without the need for lab equipment, and to look for unique DNA signatures of specific targets of interest such as Flu A, E. coli 0157 or sexually transmitted infections (STIs). 
Perelman, Jesse vanWestrienen and Marc DeJohn moved to Philadelphia last spring from New Mexico and California to participate in the DreamIt Health accelerator. From there, Biomeme went to Philadelphia’s NextFab to participate in its residency program and ramp up prototyping and low-volume manufacturing; they were the first company to utilize the partnership between Ben Franklin Technology Partners of Southeastern Pennsylvania (BFTP/SEP) and NextFab. 

Now, with a workforce of 14 (including full-timers, interns and co-op students), Biomeme is moving again into a larger facility featuring lab and manufacturing space on North 3rd Street, a burgeoning tech hub officially dubbed N3RD — pronounced “Nerd” — Street by the city.

Markets include test developers and consumers, “anyone,” explains Perelman, “who wants a DNA lab in the palm of their hand.” Biomeme has successfully completed a number of validation studies with third party laboratories and is preparing a number of developer tools for limited release this year with plans to roll out its STI test panel internationally in 2015. 

Biomeme has raised $1.9 million in seed financing, including $400,000 from BFTP/SEP.

Source: Max Perelman, Biomeme
Writer: Elise Vider